Slideshow
Author(s):
Atrial fibrillation recurrence remains a challenge amidst significant advances in managing stroke risk. Could the CHA2DS2-VASc score help?
Muvalaplin, an Oral Lp(a)-Lowering Agent, Shows Promise in Phase 2 KRAKEN Trial
Diabetes Dialogue: News and Updates in Diabetes at AHA 2024
More than 50% of US Adults Considered Eligible for Semaglutide with Current Labeling
Kidney Compass: FLOW Insights from Kidney Week 2024, with Katherine Tuttle, MD
Sacubtril/Valsartan Lowers Cardiotoxicity Risk Linked to Chemotherapy
Understanding NUDGLE-FLU Data from AHA 2024, with Ankeet Bhatt, MD, MBA, ScM